A net loss of $19.8 M or $0.24 per share in FY12 compared to a net loss of $3.9 M or $0.08 per share in FY11. Product revenue increased $400 k; while consolidated revenue decreased $900 k from Q4/11 but, CMXI has a better cash position based on thee 3 tier financing. In FY12 consolidated revenue jumped $3.4 M while product revenue increased 23% but, the net loss for FY12 increased to $19.8 M or $0.24 per share compared with $3.9 M or $0.08 per share in FY11. There was double-digit growth in Angel and AutoloGel sales – having placed more than 500 Angel Systems on a worldwide basis. Nearly 40,000 patients are currently being treated with the Angel System on an annualized basis. This capital infusion provides CMXI with the necessary capital to fund the launch of AutoloGel under CED, sales expansion for the Angel cPRP System, business development and partnering activities, and completion of the RECOVER-Stroke P2 study. “Bright Cell” technology pipeline continues to advance. CMXI is enrolling patients in the RECOVER-Stroke Trial with ALD-401. This clinical trial is currently enrolling at 9 sites and is on track to complete enrollment by the end of the year. CMXI also signed an agreement with NIH to collaborate on a P2 clinical study with ALD-301 in patients with intermittent claudication, caused by peripheral arterial disease (PAD). CMXI closed FLAT at $0.53 … with a tight trading range of $0.52 to $0.53 with moderate but, increasing volume of 381.7 K shares on from Monday’s closing price of $0.53 and on Friday’s moderate 83.2 K share volume. The 50 day moving average is lower at $0.60 as the 200 day average had fallen to $0.75. Visibility is still an issue but the financing got done! 35.78 M shares are held by insiders with a weak institutional following of .1% . Ranked a BUY with a 3-6 month target of $0.85 to $1.00!